	US 12,129,313 B2
	Anti-inflammatory use of peptide
Bengt Ingemar Samuelsson, Stockholm (SE); and Ming Gu, Jiangyin (CN)
Assigned to ENLITISA (SHANGHAI) PHARMACEUTICAL CO., LTD., Shanghai (CN)
Filed by ENLITISA (SHANGHAI) PHARMACEUTICAL CO., LTD, Shanghai (CN)
Filed on Jun. 17, 2021, as Appl. No. 17/350,795.
Application 17/350,795 is a continuation of application No. 16/628,181, granted, now 11,059,859, previously published as PCT/CN2018/094440, filed on Jul. 4, 2018.
Claims priority of application No. PCT/CN2017/091818 (WO), filed on Jul. 5, 2017.
Prior Publication US 2021/0317166 A1, Oct. 14, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/08 (2019.01); A61K 38/00 (2006.01); A61K 38/10 (2006.01); A61P 17/00 (2006.01); C07K 7/06 (2006.01); C07K 7/08 (2006.01)

CPC C07K 7/06 (2013.01) [A61P 17/00 (2018.01); A61K 38/00 (2013.01)]

14 Claims

1. A method of cosmetic treatment of inflammation, of an inflammatory disorder, and/or of a disorder or condition characterized by inflammation, which method comprises:

administering a cosmetic composition comprising an isolated decapeptide consisting of the amino acid sequence of Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys (SEQ ID NO: 1) or a cosmetically-acceptable salt thereof in admixture with a cosmetically-acceptable adjuvant, diluent or carrier, to a patient in need of such treatment.